291 related articles for article (PubMed ID: 19065669)
1. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
[TBL] [Abstract][Full Text] [Related]
2. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma.
Shi GM; Ke AW; Zhou J; Wang XY; Xu Y; Ding ZB; Devbhandari RP; Huang XY; Qiu SJ; Shi YH; Dai Z; Yang XR; Yang GH; Fan J
Hepatology; 2010 Jul; 52(1):183-96. PubMed ID: 20578262
[TBL] [Abstract][Full Text] [Related]
3. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.
Lee SJ; Lee J; Sohn I; Mao M; Kai W; Park CK; Lim HY
Anticancer Res; 2013 Nov; 33(11):5179-86. PubMed ID: 24222167
[TBL] [Abstract][Full Text] [Related]
4. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
5. Reduced N-cadherin expression is associated with metastatic potential and poor surgical outcomes of hepatocellular carcinoma.
Zhan DQ; Wei S; Liu C; Liang BY; Ji GB; Chen XP; Xiong M; Huang ZY
J Gastroenterol Hepatol; 2012 Jan; 27(1):173-80. PubMed ID: 21777276
[TBL] [Abstract][Full Text] [Related]
6. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
7. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
Yuan RH; Jeng YM; Chen HL; Hsieh FJ; Yang CY; Lee PH; Hsu HC
Clin Cancer Res; 2005 Apr; 11(7):2568-75. PubMed ID: 15814635
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
[TBL] [Abstract][Full Text] [Related]
9. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
10. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer.
Ha SY; Do IG; Lee J; Park SH; Park JO; Kang WK; Choi MG; Lee JH; Bae JM; Kim S; Kim KM; Sohn TS
Ann Surg Oncol; 2014 Apr; 21(4):1099-106. PubMed ID: 24306658
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
[TBL] [Abstract][Full Text] [Related]
12. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC
Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667
[TBL] [Abstract][Full Text] [Related]
13. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma.
Liang B; Chen R; Wang T; Cao L; Liu Y; Yin F; Zhu M; Fan X; Liang Y; Zhang L; Guo Y; Zhao J
Clin Cancer Res; 2013 Jun; 19(11):2905-16. PubMed ID: 23549880
[TBL] [Abstract][Full Text] [Related]
14. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
[TBL] [Abstract][Full Text] [Related]
17. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence.
Sun TW; Gao Q; Qiu SJ; Zhou J; Wang XY; Yi Y; Shi JY; Xu YF; Shi YH; Song K; Xiao YS; Fan J
Cancer Immunol Immunother; 2012 Nov; 61(11):2171-82. PubMed ID: 22729558
[TBL] [Abstract][Full Text] [Related]
18. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
[TBL] [Abstract][Full Text] [Related]
20. Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151.
Kim JH; Badawi M; Park JK; Jiang J; Mo X; Roberts LR; Schmittgen TD
Int J Oncol; 2016 Nov; 49(5):2037-2045. PubMed ID: 27599545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
